TRXB — TRex Bio Share Price
Last trade - 00:00- $371.07m
- $240.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 2.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.8% | ||
| Return on Equity | -72.93% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 39.11 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TRex Bio, Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The Company's Deep Biology platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across its wholly owned pipeline and through collaborations with pharma partners. Its product candidate, TRB-061, is an investigational tumor necrosis factor receptor 2 (TNFR2) agonist designed to expand and activate Tregs in inflamed tissues. TRB-071 is an investigational CD30 agonist designed to both augment tissue Tregs and block an immune system inflammatory pathway.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 24th, 2018
- Public Since
- October 9th, 2026
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 27,445,682
- Address
- 269 E. Grand Ave., Suite 300, SOUTH SAN FRANCISCO, 94080
- Web
- https://trex.bio
- Phone
- +1 6505675582
- Auditors
- KPMG LLP
Similar to TRXB
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 04:51 UTC, shares in TRex Bio are trading at $13.52. This share price information is delayed by 15 minutes.
Shares in TRex Bio last closed at $13.52 and the price had moved by over the past 365 days. In terms of relative price strength the TRex Bio share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreTRex Bio does not currently pay a dividend.
TRex Bio does not currently pay a dividend.
TRex Bio does not currently pay a dividend.
To buy shares in TRex Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $13.52, shares in TRex Bio had a market capitalisation of $371.07m.
Here are the trading details for TRex Bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TRXB
Based on an overall assessment of its quality, value and momentum TRex Bio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TRex Bio. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $13.52, shares in TRex Bio were trading -4.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TRex Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $13.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TRex Bio's directors